In silico analysis of wild-type and mutant KRAS
Abstract
Keywords
Full Text:
PDFReferences
Chen, C.C., Er, T.K., Liu, Y.Y., Hwang, J.K., Barrio, M.J., Rodrigo, M., Garcia-Toro, E., Herreros, M., 2013, Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations, PLoS ONE 8(2): e55793
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11(8):753-762
Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb. T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P.A, 2006, COSMIC 2005, Br J Cancer, 94:318–322
Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic acids research, 39: 945-950
Forbes, S.A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C.Y., Jia, M., Ewing, R., Menzies, A., Teague. J.W., Stratton, M.R., Futreal, P.A., 2009, COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res, 38: D652–D657
Futatsugi, N., and Tsuda, M., 2001, Molecular dynamics simulations of Gly-12->Val mutant of p21(ras): dynamic inhibition mechanism, Biophys J, 81:3483-3488
Gao, C., Leif, A., 2013, Impact of Mutations on KRAS-p120GAP Interaction. Computational Molecular, Bioscience, 3: 9-17
Garcea, G., Neal, C.P., Pattenden, C.J., 2005, Molecular prognostic markers in pancreatic cancer: A systematic review, Eur J Cancer, 41:2213–2236.
Hardono, B.Y., Santoso, B., and Da’i, M., 2013, Analisis Molecular Docking Energi Ikatan Turunan Diketoperazin (DKP) Sebagai Inhibitor Histon Deasetilasi (HDACi), Master Thesis, Universitas Muhammadiyah Surakarta
Hongyo, T., Buzard, G.S., Palli, D., Weghorst, C.M., Amorosi, A., Galli, M., 1995. Mutations of the KRAS and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 55:2665–2672.
Hunter, J.C., Manandhar, A., Carrasco, M.A., Gurbani, D., Gondi, S., and Westover, K.D., 2015, Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations, Mol Cancer Res. 13(9): 1325-1335
Ihle, N.T., Byers, L.A., Kim, E.S., Saintigny, P., Lee, J.J., Blumenschein, G.R., Tsao, A., Liu, S., Larsen, J.E., Wang, J., Diao, L., Coombes, .R., Chen, L., Zhang, S., Abdelmelek, M.F., Tang,X, Papadimitrakopoulou, V., Minna, J.D., Lippman, S.M., Hong, W.K., Herbst, R.S., Wistuba, I.I., Heymach, J.V., Powis, G., 2012, Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome, J Natl Cancer Inst; 104(3): 228–239
Karnoub, A.E., & Weinberg, R.A., 2008, RAS oncogenes: split personalities. Nature Reviews Molecular Cell Biology. 9: 517-53
Knickelbein, K., Zhang, L., 2014, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes and Diseases, 2(1): 4–12
Krengel, U., Schlichting, I., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, U., Pai, E.F., Wittinghofer, A., 1990, Three-dimensional structures of HRAS p21 mutants: molecular basis for their inability to function as signal switch molecules, Cell 62(3): 539–548.
Miyakura, Y., Sugano, K., Fukayama, N., Konishi, F., Nagai, H., 2002, Concurrent mutations of KRAS oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol. 32(6):219-21
Petsko, G.A., Ringe, D., 2004, Protein structure and function. London: New Science Press.
Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., Wittinghofer, A., 1997, The RAS-RASGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants, Science 277(5324):333-338
Stephen, A.G., Esposito, D., Bagni, R.K., McCrnick F., 2014, Dragging RAS back in the ring. Cancer Cell, 25:272–281.
Vatansever, S., Erman, B., Gümüş Z.H., 2017, Oncogenic G12D mutation alters local conformations and dynamics of KRAS, bioRxiv preprint first posted online Aug. 19, 2017
DOI: http://dx.doi.org/10.12928/pharmaciana.v9i1.11384
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Frengki Frengki, Dedi Prima Putra, Fatma Sriwahyuni, Daan Khambri, Henni Vanda
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Office: Faculty of Pharmacy, Universitas Ahmad Dahlan
Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta, Indonesia
Kode pos 55164
Email: pharmaciana@pharm.uad.ac.id